The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy results of node-negative HER2-amplified breast cancer subset from BCIRG 006 study: A phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin, and trastuzumab (TCH).
V. Valero
No relevant relationships to disclose
D. J. Slamon
No relevant relationships to disclose
W. Eiermann
No relevant relationships to disclose
N. J. Robert
Consultant or Advisory Role - Pfizer; Roche; Sanofi
Honoraria - Roche; Sanofi
Research Funding - Pfizer
T. Pienkowski
No relevant relationships to disclose
M. Martin
No relevant relationships to disclose
J. R. Mackey
Honoraria - Roche; Sanofi
M. A. Lindsay
No relevant relationships to disclose
V. Bee-Munteanu
No relevant relationships to disclose
M. F. Press
No relevant relationships to disclose
G. Sauter
No relevant relationships to disclose
J. Crown
Consultant or Advisory Role - Roche; Sanofi
Honoraria - Roche; Sanofi
Research Funding - Roche; Sanofi